<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653458</url>
  </required_header>
  <id_info>
    <org_study_id>ODO-P2-159</org_study_id>
    <nct_id>NCT00653458</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algorithme Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single-dose bioavailability of Kali's Ondansetron ODt 8 mg with that of&#xD;
      GlaxoSmithKine's Zofran 8 mg under fed conditions&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Kali formulated products under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received GlaxoSmithKline's formulated products under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>ODT, 8 mg, single-dose, fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Zofran ODT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zofran</intervention_name>
    <description>ODT, 8 mg, single-dose, under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Ondansetron ODT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting all of the following criteria may be included in the study&#xD;
&#xD;
          -  Availability of subject for the entire study period and willingness to adhere to&#xD;
             protocol requirements as evidenced by the informed consent from duly signed by the&#xD;
             subject.&#xD;
&#xD;
          -  Males and females aged from 18 to 50 years with a body mass index (BMI) within 19-30;&#xD;
             demographic data (sex, age, ethnic group, body weight, height and smoking habits) will&#xD;
             be recorded and reported in the final report.&#xD;
&#xD;
          -  Clinical laboratory values within the laboratory's stated normal range; if not within&#xD;
             this range, they must be without ant clinical significance and must be recorded as&#xD;
             such in the CRF ( laboratory tests are presented in section 7.1.3)&#xD;
&#xD;
          -  Healthy according to the laboratory results and physical examination.&#xD;
&#xD;
          -  Normal cardiovascular function according to the to ECG.&#xD;
&#xD;
          -  Non or ex-smokers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history of hypersensitivity to ondansetron or any related products as well&#xD;
             as severe hypersensitivity reactions (like angioedema) to any drugs.&#xD;
&#xD;
          -  Presence or history of significant gastrointestinal, liver or kidney disease, or any&#xD;
             other conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects.&#xD;
&#xD;
          -  Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic,&#xD;
             psychiatric, endocrine, immunologic or dermatologic disease.&#xD;
&#xD;
          -  Females who pregnant, lactating or are likely to become pregnant during the study&#xD;
             phases.&#xD;
&#xD;
          -  Females or childbearing potential who refuse to use an acceptable contraceptive&#xD;
             regimen throughout the study.&#xD;
&#xD;
          -  Positive pregnancy test before and during the study.&#xD;
&#xD;
          -  Maintenance therapy with any drug, or significant history of drug dependency, alcohol&#xD;
             abuse (&gt;3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or&#xD;
             serious psychological disease.&#xD;
&#xD;
          -  Any clinically significant illness in the previous 28 days before day 1 of this study.&#xD;
&#xD;
          -  Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all&#xD;
             barbiturates, corticosteroids, phenylhydantoins, etc.)&#xD;
&#xD;
          -  Participation in another clinical trial in the previous 28 days before day 1 of this&#xD;
             study.&#xD;
&#xD;
          -  Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies,&#xD;
             etc.) in the previous 56 days before day 1 of this study.&#xD;
&#xD;
          -  Positive urine screenings of drugs of abuse (drug names are presented in section&#xD;
             7.1.4).&#xD;
&#xD;
          -  Positive results to HIV, HBsAg or anti-HCV tests.&#xD;
&#xD;
          -  History of fainting upon blood sampling.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Aumais</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algotithme Pharma Inc</affiliation>
  </overall_official>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>April 4, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 10, 2008</last_update_submitted>
  <last_update_submitted_qc>April 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr.Alfred Elvin/ Diector Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>Ondansetron ODT</keyword>
  <keyword>fed</keyword>
  <keyword>To determine bioequivalence under fed conditions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

